Current Clinical Trials

Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SCUSF
Indentifier #: NCT01009918
Title: SCUSF-0806, Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin)
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: NSABP
Indentifier #: NCT01275677
Title: NSABP B47, A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: NSABP
Indentifier #: NCT00769379
Title: NSABP B43, A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: Genentech
Indentifier #: NCT01615068
Title: Genentech ML 28257; An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Walsh MD, James
Sub-Investigator(s):
  • Charles, Kevin
  • Samuel MD, Geetha
Sponsor: Internal
Indentifier #: http://www.ielcap.org/
Title: Guthrie Clinic Lung Cancer Screening Protocol
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Indentifier #: NCT02154490
Title: S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SWOG
Indentifier #: NCT01674140
Title: S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SWOG
Indentifier #: NCT01272037
Title: S1007, A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Department: Oncology
Diagnosis: Genito-urinary - Renal
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SWOG
Indentifier #: NCT01120249
Title: S0931, EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01822496
Title: RTOG 1306, A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Cancer Control
Principal Investigator: Srivatana M.D., Panit
Sponsor: Alexion
Indentifier #: NCT01374360
Title: Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry
Department: Oncology
Diagnosis: Miscellaneous
Principal Investigator: Lowry MD, Philip
Sponsor: INC
Indentifier #:
Title: INCB-MA-PV-401, PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES (REVEAL)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT00828009
Title: E6508, A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01107626
Title: E5508, Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Lowry MD, Philip
Sponsor: CALGB
Indentifier #: NCT01150045
Title: CALGB 80702, A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01286272
Title: CALGB 50904, A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT00499330
Title: CALGB 140503 - A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 cm) Peripheral Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Agheli MD, Aref
Sub-Investigator(s):
Sponsor: Amgen
Indentifier #: none
Title: Amgen 20130110; Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early-Stage (I-III) Breast Cancer Patients Neulasta
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: Amgen
Indentifier #: NONE
Title: Amgen 20130110; Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early-Stage (I-III) Breast Cancer Patients Neulasta
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: AbbVie
Indentifier #: NCT02032277
Title: M14-011, A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: Astra Zeneca
Indentifier #: NCT02000622
Title: D0819C00003, A Phase III, Open Label, Randomized, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: Pfizer
Indentifier #: NCT01525550
Title: A6181202, A Single Arm Open-Label International Multi Center Study Of The Efficacy And Safety Of Sunitinib Malate (SU011248, Sutent®) In Patients With Progressive Advanced Metastatic Well Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: ALLIANCE
Indentifier #: NCT01573442
Title: Alliance A221102, Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Indentifier #: NCT01835158
Title: Alliance A031203,Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Department: Oncology
Diagnosis: Gastrointestinal - Liver
Principal Investigator:
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT01015833
Title: CALGB 80802, Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients with Advanced Hepatocellular Carcinoma (HCC)
Department: Oncology
Diagnosis: Cancer Control
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01333033
Title: CALGB 80803,Randomized Phase II Trial of PET Scan-directed Combined Modality Therapy in Esophageal Cancer
Department: Oncology
Diagnosis: Genito-urinary - Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT00942331
Title: CALGB-90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, And Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT01169337
Title: E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG
Indentifier #: NCT00843882
Title: E2905, Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01642251
Title: E2511, Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: CTSU -NCI
Indentifier #: NCT00588770
Title: E1305, A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lynch MD, Cynthia A.
Sub-Investigator(s):
Sponsor: Celldex
Indentifier #: NCT01997333
Title: CDX011-04, A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Indentifier #: NCT01841736
Title: Alliance A021202, Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors; ClinicalTrials.gov identifier: NCT01841736